Silk Laser Australia reports a surprisingly good 1HY23 result amidst 4-decade high inflation
Nick Sundich, February 28, 2023
Silk Laser Australia (ASX:SLA) managed to grow its revenues and profit even amidst high inflation. Theoretically, skin laser treatments should be discretionary and that is why its share price has underperformed. The results tell a different story, however.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Silk Laser Australia grows its revenues and profit
Silk Laser Australia’s network cash sales in 1HY22 increased 35% to $102.8m and revenue grew 21% to $49m. The reason for the discrepancy is that it operates with a franchise model.
The company’s underlying profit increased 15% to $6.6m and its statutory profit rose 22% to $5m. It closed the period with 142 clinics, up from 122 just 6 months earlier, along with $19.4m in cash on the balance sheet.
The average customer spend was $679 and the company’s Net Promoter Score was 80.
But investorsare not giving it credit
Despite Silk Laser Australia’s performance, its shares are down nearly half since its IPO.
The company hasn’t been helped by private equity firm Advent selling roughly half its stake after the IPO. While it retains a 12% stake, there isn’t confidence that it will stick around.
Also not helping its cause have been lockdowns, the Omicron wave and fears that high inflation will cause people (mostly women in the case of this company) to cut back spending on these products.
And even though demand hasn’t decline, it did not grow exponentially either in the way that other retailers experienced.
However, if the company can continue to deliver these results, we think it is inevitable that investors will notice eventually.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Here are 3 ASX stocks fighting diabetes and the opportunity ahead of them
There aren’t many ASX stocks fighting diabetes, but the few that are have a big market opportunity ahead of them. And…
Predictive Discovery (ASX:PDI): It’s got a 4.2Moz gold deposit, but should you buy now?
Few stocks have ever gained more than 700% in a day, but Predictive Discovery (ASX:PDI) did just that back in…
PEP11 has been cancelled, and that’s bad news for these stocks
PEP11 (Petroleum Exploration Permit 11) has officially been cancelled by the federal government. Federal Industry and Science Minister Ed Husic…